Streetbeat News

Stock Prices

REGN

SNY

TSVT

Regeneron Pharmaceuticals Inc (REGN) reported a Q4 adjusted EPS of $11.86, surpassing estimates and showing a revenue increase of 1% to $3.43 billion. Dupixent sales, recorded by Sanofi (SNY), rose 31% to $3.22 billion. Regeneron's Eylea sales slightly declined, while Libtayo sales surged 44%. Additionally, Regeneron formed Regeneron Cell Medicines after acquiring assets from 2seventy bio Inc (TSVT), with REGN shares rising 3.26% in premarket trading.

Portfolio Pulse from Vandana Singh

February 02, 2024 | 4:08 pm

CHD

Church & Dwight Company, Inc. (NYSE:CHD) reported Q4 net sales of $1.528 billion, a 6.4% increase year over year, surpassing both its own and analyst expectations. Organic sales grew by 5.3%, driven by favorable price and product mix and higher volume. Adjusted EPS was $0.65, matching analyst consensus. The company saw growth in both domestic and international consumer sales but a decrease in Specialty Products' net sales. Gross margin improved due to pricing, volume, productivity, and the HERO acquisition. Church & Dwight raised its quarterly dividend by 4% and provided a positive outlook for 2024, expecting 4%-5% sales growth and 7%-9% adjusted EPS growth. Despite the positive report, CHD shares fell by 2.25% to $99.49.

Portfolio Pulse from Nabaparna Bhattacharya

February 02, 2024 | 4:02 pm

SYM

Symbotic (NASDAQ:SYM) is scheduled to release its quarterly earnings report on February 5, 2024, with an expected EPS of $-0.06. Analysts and investors are keen on not just the earnings beat but also the forward guidance. Historically, Symbotic's share price has reacted significantly to its earnings performance, with a notable 40.15% increase after last quarter's earnings beat. Over the past year, SYM shares have surged by 209.79%, indicating strong investor confidence. The upcoming earnings report is highly anticipated for its potential impact on stock performance.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

KFRC

Kforce (NASDAQ:KFRC) is scheduled to release its quarterly earnings report on February 5, 2024, with an estimated EPS of $0.79. Historically, Kforce has shown mixed results in beating EPS estimates, with a notable 8.55% share price increase following last quarter's earnings beat. Over the past year, KFRC shares have risen by 18.77%, indicating a positive outlook among long-term investors. The upcoming earnings report and particularly the company's guidance for future quarters will be critical for investors.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

IDXX

IDEXX Laboratories (NASDAQ:IDXX) is scheduled to release its quarterly earnings report on February 5, 2024, with analysts estimating an EPS of $2.11. Historical data shows that IDEXX's stock price reacts positively to earnings beats and guidance. Last quarter, IDEXX beat the EPS estimate by $0.16, leading to a 6.09% increase in its share price. Over the last year, IDXX shares have risen by 8.76%, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

ACM

AECOM (NYSE:ACM) is scheduled to release its quarterly earnings report on February 5, 2024, with analysts expecting an EPS of $0.95. The company's past earnings performance shows a mix of beats and misses, with the last quarter beating estimates by $0.03 and resulting in a 7.37% share price increase the following day. AECOM's stock has seen a 1.36% increase over the last 52 weeks, trading at $89.73 as of February 1. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

FN

Fabrinet (NYSE:FN) is scheduled to release its quarterly earnings report on 2024-02-05, with analysts expecting an EPS of $2.03. The company's past performance shows a trend of beating EPS estimates, which has often led to positive stock price movements the following day. Shares of Fabrinet have seen a 68.56% increase over the last 52 weeks, indicating a bullish sentiment among long-term shareholders. Investors will be particularly attentive to the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

CVS

Financial analysts observed unusual options activity for CVS Health (NYSE:CVS), with a bullish sentiment prevailing among significant investors. Analysis of recent trades showed 80% bullish and 20% bearish tendencies, with a focus on strike prices ranging from $50.0 to $82.5. CVS Health, a major healthcare services provider, is currently experiencing a slight decrease in stock price to $73.69, with an anticipated earnings release in 5 days. The company's diverse operations and recent acquisition of Oak Street highlight its potential for synergy and growth.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

KE

Kimball Electronics (NASDAQ:KE) is scheduled to release its quarterly earnings report on Monday, 2024-02-05, with an estimated EPS of $0.44. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for the next quarter. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's EPS miss leading to a 13.03% drop in share price. Over the last year, KE shares have decreased by 6.3%, indicating potential concerns among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm

WMT

A significant number of investors have taken a bearish stance on Walmart (NYSE:WMT), as evidenced by unusual options trading activity. Benzinga's options scanner revealed 9 uncommon trades, with a sentiment split of 33% bullish and 66% bearish. The trades focus on a price band between $125.0 and $185.0 for Walmart. The market's major players are showing interest in both puts and calls, with a total trade price for puts at $180,709 and for calls at $254,467. Walmart's current market standing shows a slight increase in stock price to $168.52, with indicators suggesting it may be overbought. The next earnings report is expected in 18 days.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 4:01 pm